Cryoport Q3 revenue down 7% YoY, net loss widens to $0.31/share; affirms FY guidance

Cryoport, Inc.

2023-Q3 EPS reported -$0.89 revenue$175,995,000

Q3 revenue $56.2M (-7% YoY); net loss $15.3M ($0.31 loss per share) vs $7.3M ($0.15 loss) in Q3 2022.
Adjusted EBITDA negative $3.1M (vs positive $4.7M a year ago); operating costs rose to $41.2M.
Commercial cell/gene therapy revenue up 54% to $6.6M; supports record 670 clinical trials (81 Phase 3).
Affirms FY2023 revenue guidance $233-243M; cash & investments $465.9M at quarter end.
Repurchased $31.3M of convertible notes for $25.1M, recording $5.7M gain on debt extinguishment.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cryoport, Inc. reported the third quarter ended September 30, 2023 results: revenue $56.2 million. Guidance reaffirmed.

Period: the third quarter ended September 30, 2023
Revenue: $56.2 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

new therapy approvals and an additional seven label/ geographic expansions or moves to earlier lines of treatment approved. Financial Highlights Total revenue for Q3 2023 was $56.2 million compared to $60.5 million for Q3 2022, a year-over-year decrease of 7% or $4.3 million. • Biopharma/Pharma revenue was $47.0 million, down 3% or $1.6 million for Q3 2023 compared

View on SEC.gov

Browse all earnings releases →

Cryoport, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-115766

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.